Abstract
The serine/arginine-rich splicing factors (SRSFs) play an important role in regulating the alternative splicing of precursor RNA (pre-RNA). During this procedure, introns are removed from the pre-RNA, while the exons are accurately joined together to produce mature mRNA. In addition, SRSFs are involved in DNA replication and transcription, mRNA stability and nuclear export, and protein translation. It is reported that SRSFs participate in hematopoiesis, development, and other important biological processes. They are also associated with the development of several diseases, particularly cancers. While the basic physiological functions and the important roles of SRSFs in solid cancer have been extensively reviewed, a comprehensive summary of their significant functions in normal hematopoiesis and hematopoietic malignancies is currently absent. Hence, this review presents a summary of their roles in normal hematopoiesis and hematopoietic malignancies.
Introduction
RNA splicing—the process of removing non-coding introns and joining coding exons—is a fundamental step in gene expression. For a long time, the factors controlling this process were viewed as "housekeeping" components. However, recent research has shown that these factors, particularly the serine/arginine-rich splicing factor (SRSF) family, are highly specific regulators. This review, published in Cancer Cell International (2024), synthesizes findings from over 120 primary research papers to map out the diverse molecular functions of SRSFs and their critical roles in blood cell production and malignancy.
Molecular Versatility of SRSFs
SRSFs are multi-talented proteins that act as master regulators of gene expression. Beyond their well-known role in alternative splicing, they are involved in the entire lifecycle of mRNA, including DNA replication, transcription, mRNA stability, nuclear export, and even protein translation. These factors interact with the spliceosome and other cellular machinery to ensure the accurate production of mature mRNA. Dysregulation at any of these stages can lead to significant phenotypic shifts, such as the failure of blood stem cells to mature or the development of drug resistance.
SRSFs in Normal Hematopoiesis
SRSFs are essential for healthy blood development, acting as cell-fate determinants that control critical "switches" in maturation. For example, the balance between two isoforms of the NUMB gene, regulated by SRSF2, determines whether a cell remains a progenitor or matures. Specific SRSFs like SRSF2, 3, and 5 are necessary at different stages of hematopoiesis, from mesodermal cells to mature platelets and red blood cells. SRSF3, in particular, is essential for megakaryocyte maturation; its loss leads to megakaryocytosis—an overabundance of immature megakaryocytes and a lack of functional platelets.
Dysregulation in Hematological Malignancies
In blood cancers, SRSFs are frequently hijacked. A single proline-to-histidine mutation at position 95 in SRSF2 (P95H) is a recurring "hotspot" mutation in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). This mutation changes the protein's affinity for specific RNA sequences, leading to a "mis-splicing" cascade that promotes leukemogenesis. SRSF2 mutations are found in approximately 25% of AML patients and are linked to poor prognosis, causing aberrant splicing of genes like CSF3R and EZH2.
Other malignancies also show specific SRSF involvement:
- Chronic Myeloid Leukemia (CML): High levels of SRSF1 are associated with resistance to imatinib by altering the splicing of the pro-apoptotic gene BIM.
- B-cell ALL: Low levels of SRSF3 lead to the skipping of exon 2 in the CD19 gene. This creates a truncated CD19 protein that CAR-T cells cannot recognize, leading to treatment failure and drug resistance.
Future Perspectives and Therapeutic Challenges
While SRSFs present promising therapeutic targets, several challenges remain. Small molecule inhibitors of CLK (kinases that regulate SRSFs) are in Phase I trials, but they currently lack the specificity needed to target only mutant versions of splicing factors. Furthermore, the predictive logic determining which specific splicing events an SRSF will regulate in a given cell type is still unclear. Future research must expand beyond SRSF2 to explore the therapeutic potential of other family members like SRSF10 and SRSF6 to bridge the current therapeutic gap in hematological oncology.
Summary updated